Diagnostic hapten-carrier conjugates BSA-[M], OVA-[M], KLH-[M] for [E] [G] detection in Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Product Details
Digoxin, sold under the brand name Lanoxin among others, is a medication used to treat various heart conditions.[4] Most frequently it is used for atrial fibrillation, atrial flutter, and heart failure.[4] Digoxin is one of the oldest medications used in the field of cardiology.Genemedi produces core diagnostic ingredients for test of cardiovascular disease and related syndrome.
GeneMedi offers Diagnostic hapten-carrier conjugates BSA-digoxigenin (Digoxin), OVA-digoxigenin (Digoxin), KLH-digoxigenin (Digoxin) for cardiovascular disease Digoxin detection in Competitive immunoassay validation (Competitive ELISA), Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for cardiovascular disease test are suitable for in functional ELISA, and other immunoassays in dignostics.
Product Description
|
Cat No.
|
GMP-SMT-Digoxin-Ag
|
|
Product Name
|
BSA-digoxigenin (Digoxin) / OVA-digoxigenin (Digoxin)
|
|
Expression platform
|
Synthetic
|
|
Bioactivity validation
|
digoxigenin (Digoxin) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Digoxin level test of Cardiovascular disease and related syndrome evaluation
|
|
Products description
|
Competitive immunoassay-validated hapten-carrier conjugates BSA-digoxigenin (Digoxin) / OVA-digoxigenin (Digoxin) is Synthetic.
|
|
Purity
|
|
|
Application
|
Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
|
|
Formulation
|
Lyophilized from sterile PBS, PH 7.4
|
|
Storage
|
Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
|
|
Cat No.
|
GMP-SMT-Digoxin-Ag
|
|
Product Name
|
|
|
Expression platform
|
|
|
Isotypes
|
|
|
Bioactivity validation
|
|
|
Tag
|
|
|
Products description
|
|
|
Specics
|
|
|
Purity
|
|
|
Application
|
|
|
Formulation
|
|
|
Storage
|
|
Diagnostic antibodies and antigens for Epilepsy-related valproate (VPA) toxicity testing: Sodium valproate (VPA)
Valproate is a commonly used antiepileptic drug for the treatment of epilepsy and seizures. It is safe for use in both adults and children more than three years of age. Valproate toxicity can occur both accidentally and intentionally. Acute valproate overdose usually presents with CNS depression/encephalopathy, electrolyte abnormalities such as hypernatremia, elevated transaminase levels, hyperammonemia, and hepatoxicity. In patients with a severe overdose of valproate, patients can present with hypotension, tachycardia, respiratory depression, metabolic acidosis, cerebral edema, and valproate-related hyperammonemic encephalopathy which may progress to coma and death. GENEMEDI developed the Gastrin-17 (G-17) antigens and antibodies for the diagnosis of valproate toxicity based on ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
